Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
CC transcript
Inv. presentation
SALIX PHARMACEUTICALS LTD (SLXP) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/01/2015 8-K Form 8-K - Current report
03/16/2015 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ¨ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ¨ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Item 1.01. Entry into a Material Definitive Agreement. On March 16, 2015, Salix Pharmaceuticals, Ltd., a Delaware corporation , Valeant Pharmaceuticals International, Inc., a British Columbia corporation , Valeant Pharmaceuticals International, a Delaware corporation and a wholly-owned su...",
"Amendment No. 1 to the Agreement and Plan of Merger, among Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, Sun Merger Sub, Inc. and Salix Pharmaceuticals, Ltd",
"VALEANT AND SALIX AGREE ON AMENDED TERMS TO MERGER AGREEMENT"
03/02/2015 8-K Quarterly results
Docs: "FORM 8-K",
"Salix Pharmaceuticals Reports 4Q2014 and FY2014 Results"
02/27/2015 8-K Other Events
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ¨ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ¨ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Item 8.01 Other Events."
02/23/2015 8-K Other Events
Docs: "FORM 8-K"
02/23/2015 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Valeant Pharmaceuticals International, Sun Merger Sub, Inc., Valeant Pharmaceuticals International, Inc., and Salix Pharmaceuticals, Ltd",
"VALEANT TO ACQUIRE SALIX PHARMACEUTICALS FOR $158.00 PER SHARE IN CASH"
02/17/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "SALIX PHARMACEUTICALS ANNOUNCES 4Q AND FY2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST"
02/13/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "License Agreement"
02/05/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "FORM 8-K",
"Salix Announces the Promotion of William P. Forbes, PharmD to President, Medical, R&D and Chief Development Officer"
02/02/2015 8-K Other Events
Docs: "FORM 8-K"
01/30/2015 8-K/A Regulation FD Disclosure, Financial Statements and Exhibits
01/28/2015 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Regulation FD D...
Docs: "Salix Provides Update on Audit Committee Review Audit Committee Determines to Restate Financial Statements for FY2013 and First Three Quarters of 2014"
01/12/2015 8-K Entry into a Material Definitive Agreement
01/09/2015 8-K Other Events, Financial Statements and Exhibits
Docs: "PHARMING AND SALIX ANNOUNCE FIRST PATIENT TREATED IN CLINICAL STUDY OF RUCONEST ® FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA"
01/05/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Retirement Agreement, among Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Carolyn J. Logan",
"Carolyn Logan to Retire as Chief Executive Officer of Salix Pharmaceuticals"
12/16/2014 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Salix Pharmaceuticals Provides Updates on Wholesaler Inventory Reductions and the XIFAXAN ® 550 for IBS-D Approval Timeline, and Provides Preliminary Guidance for 2015 and 2016"
11/24/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Salix Pharmaceuticals Announces Plan to Augment Board of Directors"
11/06/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ¨ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ¨ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 5, 2014, Adam C. Derbyshire tendered his resignation as the Executive Vice President, Finance and Administration, and C...",
"Letter Agreement, among Salix Pharmaceuticals, Ltd., Salix Pharmaceuticals, Inc. and Adam C. Derbyshire",
"Salix Pharmaceuticals Appoints Acting Chief Financial Officer"
11/06/2014 8-K Quarterly results
Docs: "Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ¨ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ¨ Pre-commencement communications pursuant to Rule 13e-4 under the Exchange Act ) Item 2.02. Results of Operations and Financial Condition. On November 6, 2014, Salix Pharmaceuticals, Ltd. issued a press release announcing its operating results for the third quarter ended September 30, 2014. A copy of the press release is attached hereto as Exhibit 99.1. The informatio...",
"Salix Pharmaceuticals Reports 3Q2014 Results"
11/04/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Second Amendment to License Agreement (Mesalamine), between Salix Inc. and Falk",
"First Amendment to License Agreement (Budesonide), between Salix Inc. and Falk",
"Salix and Pharming Announce the Launch of RUCONEST ® in the U.S. for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema RUCONEST ® 50 IU/kg IS THE FIRST AND ONLY RECOMBINANT TREATMENT OPTION AVAILABLE IN THE U.S. FOR ADULT AND ADOLESCENT PATIENTS SUFFERING FROM HAE"
10/23/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Salix's TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg for Irritable Bowel Syndrome with Diarrhea",
"SALIX PHARMACEUTICALS ANNOUNCES 3Q2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST"
10/17/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Amendment Number Three to Supply Agreement, between Salix Inc. and Alfa",
"Amendment Number Four to Supply Agreement, between Salix Inc. and Alfa",
"SALIX PHARMACEUTICALS OUTLINES DATA PRESENTATIONS AT AMERICAN COLLEGE OF GASTROENTEROLOGY 2014 ANNUAL SCIENTIFIC MEETING"
10/08/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA Approves UCERIS® 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Field Promotion to Launch January 2015"
10/06/2014 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statement...
Docs: "Termination Agreement, by and among Salix Pharmaceuticals, Ltd., Cosmo Pharmaceuticals S.p.A., Cosmo Holding S.p.A., Cosmo Technologies Limited and Sangiovese, LLC",
"Salix Pharmaceuticals and Cosmo Technologies Announce Termination of Merger Agreement"
09/30/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA Approves RELISTOR ® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain"
09/22/2014 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Settlement Agreement",
"Salix Announces FDA User Fee Goal Date of February 28, 2015 for XIFAXAN ® 550mg sNDA for Treatment of Irritable Bowel Syndrome with Diarrhea Results of XIFAXAN ® 550mg TARGET 3 Study Selected by American College of Gastroenterology for Oral Presentation at Annual Meeting"
09/18/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "SALIX SECURES ADDITIONAL INTELLECTUAL PROPERTY RELATING TO RIFAXIMIN"
09/16/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "UCERIS® 2mg Rectal Foam for the Induction of Remission of Mild-to-Moderate Distal Ulcerative Colitis Granted Tentative Approval by FDA"
09/02/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Salix Submits Response to XIFAXAN ® 550mg Complete Response Letter Regarding Repeat Treatment for Irritable Bowel Syndrome with Diarrhea"
08/19/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "Salix Announces Early Termination of HSR Waiting Period for Pending Transaction"
08/12/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "FDA Assigns September 29, 2014 Prescription Drug User Fee Act Goal Date for RELISTOR ® Subcutaneous Injection sNDA for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain",
"SALIX ANNOUNCES IMPORTANT TOPLINE RESULTS FOR MICROBIOME, CULTURE & SUSCEPTIBILITY, AND KEY SECONDARY EFFICACY RESULTS FOR TARGET 3, RIFAXIMIN IBS-D REPEAT TREATMENT STUDY Most Comprehensive Microbiome Data Set in IBS Patients to Date with More than Two Billion Data Points Collected Longitudinal Samples Demonstrate Microbiome Stability with Repeat Rifaximin Dosing Alterations in Antibiotic Susceptibility for Potential Major Pathogens were not Apparent with Repeat Rifaximin Use Key Secondary Efficacy Endpoints Support Positive Top-Line Primary Efficacy Results"
08/07/2014 8-K Quarterly results
Docs: "Salix Pharmaceuticals Reports 2Q2014 Results"
07/24/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "SALIX PHARMACEUTICALS ANNOUNCES 2Q2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST"
07/17/2014 8-K Other Events, Financial Statements and Exhibits
Docs: "SALIX AND PHARMING ANNOUNCE FDA APPROVAL OF RUCONEST ® FOR THE TREATMENT OF ACUTE ANGIOEDEMA ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA RUCONEST ® 50 IU/kg IS THE FIRST AND ONLY RECOMBINANT TREATMENT OPTION FOR ADULT AND ADOLESCENT PATIENTS SUFFERING FROM HEREDITARY ANGIOEDEMA"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy